Athira Pharma, Inc. (ATHA)
NASDAQ: ATHA · Real-Time Price · USD
0.2800
+0.0100 (3.70%)
At close: May 13, 2025, 4:00 PM
0.2716
-0.0084 (-3.00%)
Pre-market: May 14, 2025, 8:12 AM EDT
Company Description
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase.
The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.
Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Mark Litton |
Contact Details
Address: 18706 North Creek Parkway, Suite 104 Bothell, Washington 98011 United States | |
| Phone | 425 620 8501 |
| Website | athira.com |
Stock Details
| Ticker Symbol | ATHA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001620463 |
| CUSIP Number | 04746L104 |
| ISIN Number | US04746L1044 |
| Employer ID | 45-3368487 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark J. Litton M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Kevin Church Ph.D. | Chief Scientific Officer |
| Mark F. Worthington J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Robert Renninger | Senior Vice President of Finance and Accounting, Principal Financial Officer and Principal Accounting Officer |
| Julie Rathbun | Head of Investor Relations |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 16, 2025 | 8-K | Current Report |
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |